The QUID-NASH and PharmaNest enter a partnership for the study of NASH - The EE

The QUID-NASH and PharmaNest enter a partnership for the study of NASH

Paris, France – The QUID-NASH research consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) announced that they have entered a partnership that will support the development and validation of a virtual liver biopsy (non-invasive) and artificial intelligence (AI)-powered tool for the diagnosis and staging of NASH (non-alcoholic steatohepatitis) in patients with type 2 diabetes (T2D).

The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care. The data collected (imaging, deep clinico-biological phenotyping, different omic approaches, extracellular vesicles and immune blood cell profiling) will be analysed with the Swiss Institute of Bioinformatics (SIB) and Bichat biostatistical teams through comprehensive and deep bioinformatics and biostatistics. 

Through its cloud-based, digital pathology platform FibroNest, PharmaNest will generate single-fibre and single-nuclei high-content quantitative histological datasets from each digital biopsy image to generate continuous scores that quantify the phenotypes of fibrosis and stage the severity of fibrosis and disease activity of NASH. This dataset will enrich the data collected and enable the consortium to discover novel histological phenotypes of NASH in T2D  patients.

“The quantitative FibroNest method resolves the limitation of the current categorical and semi-quantitative methods and paradigms used of the histological assessment of liver biopsies,” says Valerie Paradis, chair of the pathology department at Beaujon Hospital and leader of the INSERM team.

“PharmaNest is excited to enable the QUID NASH consortium to enter the research field of Pathomic-Fusion and provide a robust and automated method for the quantification of the fibrosis,” says Mathieu Petitjean, Ph.D., CEO of PharmaNest, Inc. 

“The addition of FibroNest’s Digital Pathology and Artificial intelligence capabilities to the QUID-NASH consortium will enhance performance of our upcoming virtual biopsy tests and generate significant upside for the investigation and understanding of NASH in T2D patients,” says Dominique Valla, principal investigator and founding director of the french reference centre for vascular diseases of the liver.

Follow us and Comment on Twitter @TheEE_io

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.